LEADER 05404nam 2200661Ia 450 001 9910139473803321 005 20200520144314.0 010 $a1-282-68839-1 010 $a9786612688393 010 $a0-470-56141-6 010 $a0-470-56140-8 035 $a(CKB)2550000000005941 035 $a(EBL)477779 035 $a(OCoLC)609853664 035 $a(SSID)ssj0000354545 035 $a(PQKBManifestationID)11276005 035 $a(PQKBTitleCode)TC0000354545 035 $a(PQKBWorkID)10314524 035 $a(PQKB)11457422 035 $a(MiAaPQ)EBC477779 035 $a(Au-PeEL)EBL477779 035 $a(CaPaEBR)ebr10360991 035 $a(CaONFJC)MIL268839 035 $a(PPN)243307217 035 $a(EXLCZ)992550000000005941 100 $a20090519d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNovel therapeutic targets for anti-arrhythmic drugs$b[electronic resource] /$fedited by George E. Billman 210 $aHoboken, NJ $cJohn Wiley & Sons$dc2010 215 $a1 online resource (612 p.) 300 $aDescription based upon print version of record. 311 $a0-470-26100-5 320 $aIncludes bibliographical references and index. 327 $aNOVEL THERAPEUTIC TARGETS FOR ANTIARRHYTHMIC DRUGS; CONTENTS; Acknowledgments; Contributors; 1. Introduction; References; 2. Myocardial K(+) Channels: Primary Determinants of Action Potential Repolarization; 2.1 Introduction; 2.2 Action Potential Waveforms and Repolarizing K(+) Currents; 2.3 Functional Diversity of Repolarizing Myocardial K(+) Channels; 2.4 Molecular Diversity of K(+) Channel Subunits; 2.5 Molecular Determinants of Functional Cardiac I(to) Channels; 2.6 Molecular Determinants of Functional Cardiac I(K) Channels; 2.7 Molecular Determinants of Functional Cardiac Kir Channels 327 $a2.8 Other Potassium Currents Contributing to Action Potential Repolarization2.8.1 Myocardial K(+) Channel Functioning in Macromolecular Protein Complexes; References; 3. The "Funny" Pacemaker Current; 3.1 Introduction: The Mechanism of Cardiac Pacemaking; 3.2 The "Funny" Current; 3.2.1 Historical Background; 3.2.2 Biophysical Properties of the I(f) Current; 3.2.3 Autonomic Modulation; 3.2.4 Cardiac Distribution of I(f); 3.3 Molecular Determinants of the I(f) Current; 3.3.1 HCN Clones and Pacemaker Channels; 3.3.2 Identification of Structural Elements Involved in Channel Gating 327 $a3.3.3 Regulation of Pacemaker Channel Activity: "Context" Dependence and Protein-Protein Interactions3.3.4 HCN Gene Regulation; 3.4 Blockers of Funny Channels; 3.4.1 Alinidine (ST567); 3.4.2 Falipamil (AQ-A39), Zatebradine (UL-FS 49), and Cilobradine (DK-AH269); 3.4.3 ZD7288; 3.4.4 Ivabradine (S16257); 3.4.5 Effects of the Heart Rate Reducing Agents on HCN Isoforms; 3.5 Genetics of HCN Channels; 3.5.1 HCN-KO Models; 3.5.2 Pathologies Associated with HCN Dysfunctions; 3.6 HCN-Based Biological Pacemakers; References; 4. Arrhythmia Mechanisms in Ischemia and Infarction; 4.1 Introduction 327 $a4.1.1 Modes of Ischemia, Phases of Arrhythmogenesis4.1.2 Trigger-Substrate-Modulating Factors; 4.2 Arrhythmogenesis in Acute Myocardial Ischemia; 4.2.1 Phase 1A; 4.2.2 Phase 1B; 4.2.3 Arrhythmogenic Mechanism: Trigger; 4.2.4 Catecholamines; 4.3 Arrhythmogenesis During the First Week Post MI; 4.3.1 Mechanisms; 4.3.2 The Subendocardial Purkinje Cell as a Trigger 24-48 H Post Occlusion; 4.3.3 Five Days Post-Occlusion: Epicardial Border Zone; 4.4 Arrhythmia Mechanisms in Chronic Infarction; 4.4.1 Reentry and Focal Mechanisms; 4.4.2 Heterogeneity of Ion Channel Expression in the Healthy Heart 327 $a4.4.3 Remodeling in Chronic Myocardial Infarction4.4.4 Structural Remodeling; 4.4.5 Role of the Purkinje System; References; 5. Antiarrhythmic Drug Classification; 5.1 Introduction; 5.2 Sodium Channel Blockers; 5.2.1 Mixed Sodium Channel Blockers (Vaughan Williams Class Ia); 5.3 Inhibitors of the Fast Sodium Current with Rapid Kinetics (Vaughan Williams Class Ib); 5.3.1 Lidocaine; 5.3.2 Mexiletine; 5.4 Inhibitors of the Fast Sodium Current with Slow Kinetics (Vaughan Williams Class Ic); 5.4.1 Flecainide; 5.4.2 Propafenone 327 $a5.5 Inhibitors of Repolarizing K(+) Currents (Vaughan Williams Class III) 330 $aProfiles potential treatment approaches for cardiac arrhythmias Cardiac arrhythmias of ventricular origin are responsible for the deaths of nearly half a million Americans each year while atrial fibrillation accounts for about 2.3 million cases per year, a rate that is projected to increase 2.5 fold over the next half century. Effectively managing these cardiac rhythm disorders remains a major challenge for both caregivers and the pharmaceutical industry. Filling a gap in the current literature, Novel Therapeutic Targets for Antiarrhythmic Drugs presents the latest treatments f 606 $aMyocardial depressants 606 $aArrhythmia$xChemotherapy 615 0$aMyocardial depressants. 615 0$aArrhythmia$xChemotherapy. 676 $a615.716 676 $a616.128061 701 $aBillman$b George Edward$f1954-$0991801 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910139473803321 996 $aNovel therapeutic targets for anti-arrhythmic drugs$92269796 997 $aUNINA LEADER 03891nam 2200721 450 001 9910787934003321 005 20200903223051.0 010 $a90-04-27445-6 024 7 $a10.1163/9789004274457 035 $a(CKB)2670000000571179 035 $a(EBL)1815789 035 $a(SSID)ssj0001347156 035 $a(PQKBManifestationID)11888000 035 $a(PQKBTitleCode)TC0001347156 035 $a(PQKBWorkID)11344273 035 $a(PQKB)11154342 035 $a(MiAaPQ)EBC1815789 035 $a(OCoLC)895116557$z(OCoLC)893333672 035 $a(nllekb)BRILL9789004274457 035 $a(Au-PeEL)EBL1815789 035 $a(CaPaEBR)ebr10953614 035 $a(CaONFJC)MIL651267 035 $a(OCoLC)893333672 035 $a(PPN)184932084 035 $a(EXLCZ)992670000000571179 100 $a20141021h20152015 uy 0 101 0 $aeng 135 $aurun| uuuua 181 $ctxt 182 $cc 183 $acr 200 10$aCategorization and constructional change in Spanish expressions of 'becoming' /$fDamia?n Vergara Wilson 210 1$aLeiden, Netherlands :$cBrill,$d2015. 210 4$d©2015 215 $a1 online resource (255 p.) 225 1 $aBrill's Studies in Historical Linguistics,$x2211-4904 ;$vVolume 4 300 $aIncludes index. 300 $aRevised from author's dissertation "Formulaic language and adjective categories in eight centuries of the Spanish expression of 'becoming' /quedar(se)/ + ADJ", University of New Mexico, 2009. 311 $a90-04-27444-8 311 $a1-322-19987-6 320 $aIncludes bibliographical references and index. 327 $aPreliminary Material -- 1 Introduction -- 2 ?Becoming? in Spanish -- 3 Data and Methods -- 4 Overview of quedar(se) + adj through Time -- 5 The solo ?Alone? Clusters: Continual Expansion with a Robust Central Member -- 6 The rico / pobre ?Rich / Poor? Clusters: The Relationship of Opposites in Category Development -- 7 The alegre / satisfecho ?Happy / Satisfied? Clusters: Family Resemblance and Changing Central Members -- 8 Similarity Experiment -- 9 Conclusion -- Appendix 1: Adjective Clusters and Tables not Analyzed -- Appendix 2: Sources in the qad -- Works Cited -- Index. 330 $aIn Categorization and Constructional Change Damián Vergara Wilson uses the Spanish change-of-state construction quedar(se) + ADJ to analyze the impact of categorization on constructional change and productivity in data spanning eight centuries. In usage, the appearance of one adjective in the construction triggers the emergence of related ones through analogical extension propelling the expansion of semantic categories of adjectives. Categories develop in different ways reflecting the characteristics of their members in terms of semantics and conventionalization. Emergence tends to relate to the ability of one construction to attract adjective types away from another. This study gives insight into the cognitive status and complex evolution of a schematic construction in a way that supports an instance-based model of memory. 410 0$aBrill's studies in historical linguistics ;$vVolume 4. 606 $aSpanish language$xFigures of speech 606 $aSpanish language$xVerb 606 $aSpanish language$xAdverbs 606 $aHistorical linguistics 606 $aConstruction grammar 615 0$aSpanish language$xFigures of speech. 615 0$aSpanish language$xVerb. 615 0$aSpanish language$xAdverbs. 615 0$aHistorical linguistics. 615 0$aConstruction grammar. 676 $a465/.6 700 $aVergara Wilson$b Damia?n Chase$01474351 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910787934003321 996 $aCategorization and constructional change in Spanish expressions of 'becoming$93688000 997 $aUNINA